vTv Therapeutics (FRA:5VT0) Short Interest


FRA:5VT0 vTv Therapeutics Inc FRA:5VT0
35 GF Score
Price €30.40
GF Value €6,657.81
View Full Analysis

What is vTv Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:5VT0 vs CRDF, GUTS, ACOG: Short Interest Comparison

For the Biotechnology subindustry, vTv Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

vTv Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where vTv Therapeutics's Short Interest falls into.


FRA:5VT0
35GF Score
vTv Therapeutics Inc FRA:5VT0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is vTv Therapeutics (FRA:5VT0) Overvalued in 2026?

Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued. The current stock price of €30.40 is trading 99.5% below its estimated GF Value™ of €6,657.81.

Key valuation signals for FRA:5VT0:

  • Short Interest:
  • GF Value™: €6,657.81 vs. price of €30.40 (99.5% below fair value)
  • GF Score™: 35/100

No single metric tells the full story. See the FRA:5VT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

vTv Therapeutics Business Description

Other Exchanges VTVT:USA
Address 3980 Premier Drive, Suite 110, High Point, NC, USA, 27265
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score

Get the complete analysis for FRA:5VT0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.40
Price
€6,657.81
GF Value